Newsletter | January 23, 2020

01.23.20 -- Biosimilar Experts Dish On 2020 Challenges

 
Featured Editorial
Education, Patents, Sustainability, Oh My! Experts Dish On 2020 Biosimilar Challenges
 
By Anna Rose Welch, editor, Biosimilar Development

In this final installment of the “Biosimilar Editorial Board 2020 Outlook” series, it's clear there is a growing urgency and passion for seeing this industry succeed — and that passion is not to be underestimated.

Biosimilar Litigation Review: Ongoing BPCIA District Court Cases To Watch
 
By Philip Chen, et.al., Fish & Richardson P.C.

BPCIA litigants and district courts grappled with new issues in 2019. The Federal Circuit has also been busy, with numerous BPCIA issues pending and a handful of new decisions issued this year. In Part 1 of this article series, we briefly summarize overall statistics regarding BPCIA district court litigation and review ongoing BPCIA district court cases.

CMS Star Ratings: Will Biosimilars Benefit?
 
By Ronald W. Lanton III

For years now, we have witnessed several debates on how biosimilars could potentially lower drug costs, and this proposed legislation is another example of the potential promise that biosimilars have in helping policymakers lower drug costs. But will this bill help?

Sponsor
Participate! 17th Annual Biopharmaceutical Manufacturing Report And Survey.

The bioindustry's most in-depth, global benchmarking and analysis study: Your input is important as we benchmark current global and regional trends affecting the bioindustry. This survey takes 15 to 25 minutes, depending on your areas of expertise. Click here.

Industry Insights
The Current Landscape For Developing Biosimilars In India
Article | By Ankita Bhargava, GE Healthcare Life Sciences

As India’s biosimilar market moves toward a promising future, it is important to gain an overview of the current regulatory and clinical expectations in India for biosimilar products.

Standing Out In The Crowded Biopharma CDMO Market
Webinar | ISR Reports

When CDMOs understand what motivates drug innovators to outsource, who is involved in the service provider selection decision, and which CDMO attributes have the greatest influence on CDMO selection, they are able to communicate what is unique about their offering to the right audience at the right time. 

Connect With Biosimilar Development:
      Twitter